RxDoctor Payments Data

Jon McGough, MD

Internal Medicine · Athens, GANPI 1639499254

Payments from drug & device makers

$413in general payments, 2019–2025

Across 10 payments — averaging $41.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$250
  • Pfizer$59
  • Sanofi-aventis U.S. LLC$24
  • Dexcom, Inc.$24
  • Lilly USA, LLC$22
  • GSK$18
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$413100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$413 in reported general payments places this provider in the 50th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$215,204
Medicare patients
592
Services billed
2,644

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban157$183,540
OzempicSemaglutide95$133,360
JardianceEmpagliflozin101$130,918
MounjaroTirzepatide77$114,117
TrulicityDulaglutide59$81,987
XareltoRivaroxaban45$55,928
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$12,339
FarxigaDapagliflozin Propanediol14$11,357
Atorvastatin Calcium755$9,941
PremarinEstrogens, Conjugated16$9,463
Lantus SolostarInsulin Glargine,hum.Rec.Anlog53$8,849
Rosuvastatin Calcium440$8,228
Aripiprazole25$7,871
DuleraMometasone/Formoterol17$6,387
Celecoxib83$4,923

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$22$196,104136 claims
PfizerEliquis, Premarin$59$193,003173 claims
GSKTrelegy Ellipta$18$12,33915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Athens

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →